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158a Sunday, February 26, 2012PKA-treatment did not alter myofilament Ca2þ-sensitivity in the TNNT2 and
TPM1 samples, whereas Ca2þ-sensitivity was significantly reduced in the
TNNI3 to values observed in donor.
PKA-pretreatment did not restore the reduced length-dependent activation of
HCM-groups.
Conclusions
Perturbed length-dependent activation may represent a feature of HCM and
contribute to impaired cardiac function in HCM-patients. Our data show that
responsiveness to b-adrenergic receptor stimulation mimicked by PKA-
treatment is absent in a HCM-homozygous TNNT2 mutation. Although hearts
with a mutation in TPM1 and TNNI3 responded to PKA, evident from a reduc-
tion in myofilament Ca2þ-sensitivity, the blunted length-dependent activation
was not corrected by PKA.
784-Pos Board B570
Impact of Site Specific Phosphorylation of the Protein Kinase a Sites Ser23
and Ser24 of Cardiac Troponin I on Contractile Function in Human
Cardiomyocytes
Paul J.M. Wijnker1, D. Brian Foster2, Allison Coulter2, Aisha Frazier2,
Anne M. Murphy2, Ger J.M. Stienen1, Jolanda van der Velden1.
1VU University Medical Center, Amsterdam, Netherlands, 2Johns Hopkins
University School of Medicine, Baltimore, MD, USA.
Protein kinase A (PKA)-mediated phosphorylation of contractile proteins upon
activation of b-adrenergic receptors decreases myofilament Ca2þ-sensitivity
and accelerates relaxation of the heart. Phosphorylation of the PKA sites
(Ser23/24) of cardiac troponin I (cTnI) is decreased in end-stage failing com-
pared to non-failing human hearts. However, the site-specific functional conse-
quences of phosphorylation at these sites in human myocardium are unknown.
Therefore, we studied the effect of phosphorylation of cTnI-Ser23/24 on myo-
filament function in explanted human heart tissue.
Myofilament force development was measured at various [Ca2þ] in permeabi-
lized cardiomyocytes in which endogenous troponin complex was partially ex-
changed (6952%) with recombinant (Myc-tag labeled) whole human troponin
complexes (1 mg/ml). Site-directed mutations were used to mimic phosphory-
lation of both Ser23 and Ser24 (cTnI-DD), Ser24 only (cTnI-AD), Ser23 only
(cTnI-DA) or dephosphorylation of both sites (cTnI-AA).
In donor cardiomyocytes,myofilament Ca2þ-sensitivity (pCa50) was signifi-
cantly reduced in cTnI-DD (pCa50=5.3950.01) compared to cTnI-AA
(pCa50=5.5050.01), cTnI-AD (pCa50=5.4850.01) and cTnI-DA
(pCa50=5.5150.01). The maximal rate of tension redevelopment (ktr) was de-
creased by 15.1-19.8% in cTnI-AD compared to cTnI-AA, cTnI-DA and cTnI-
DD. Pseudo-phosphorylation of Ser23/24 had no effect on maximal or passive
force nor on the steepness of the force-pCa relation. In end-stage failing cardi-
omyocytes, using cTnI-DD concentrations between 0 and 1 mg/ml in order to
vary the degree of exchange, a linear decline in the pCa50 vs cTnI-DD content
by 0.1350.03 units was observed, saturating at 5257% of cTnI-DD.
Our data indicate that (1) pseudo-phosphorylation of both PKA-sites on cTnI is
required to reduce myofilament Ca2þ-sensitivity, (2) pseudo-phosphorylation
of Ser24 on cTnI results in a slowing of crossbridge kinetics and (3) the max-
imal reduction in pCa50 is reached at ~50% bis-phosphorylated cTnI.
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Background: One of the mutated sarcomeric proteins in familial hypertrophic
cardiomyopathy (FHC) is Troponin I (cTnI), a down-stream target of the b-ad-
renergic receptor pathway. Activation of this pathway leads to protein kinase A
(PKA)-mediated phosphorylation of cTnI and sarcomere desensitization to
Ca2þ to improve muscle relaxation. Moreover, cTnI phosphorylation was
shown to enhance sarcomere length-dependent activation (i.e. Frank-Starling
mechanism). We investigated if the responsiveness to PKA and to an increase
in sarcomere length is impaired by mutant cTnI in human FHC.
Methods: A comparison was made between cardiac samples from two FHC pa-
tients harboring the R145W mutation in the TNNI3 gene (TNNI3mut) and non-
failing donor hearts. Isometric force was measured in Triton-permeabilized
cardiomyocytes at different [Ca2þ] and sarcomere lengths of 1.8 and 2.2 mm
before and after treatment with exogenous PKA.Results: At a sarcomere length of 2.2 mm, TNNI3mut cells (n=30) showed lower
maximal force (26.354.9 kN/m2) and similar passive force (2.150.2 kN/m2)
compared to donor cells (n=48; 36.452.3 and 2.450.3 kN/m2, respectively).
In addition, a significantly higher Ca2þ-sensitivity (EC50)(2.6950.16 mM) and
a decreased steepness (2.1750.10) of the force-Ca2þ relation were found in
TNNI3mut compared to donor (3.0950.09 mM and 3.7550.12, respectively).
The increase in Ca2þ-sensitivity (i.e. length-dependent activation; DEC50)
upon an increase in sarcomere length was significantly smaller in TNNI3mut
(0.2950.15) compared to donor (0.7650.06) cells. Treatment with PKA de-
creased myofilament Ca2þ-sensitivity in TNNI3mut to values observed in donor,
but did not correct the reduced length-dependent activation.
Conclusions: Our data show preserved responsiveness to PKA in FHC harbor-
ing the R145Wmutation, but a blunted length-dependent activation, which was
not corrected by PKA. Reduced maximal force and perturbed Frank-Starling
mechanism, both at baseline and after PKA, may impair contractile perfor-
mance in human FHC with mutant cTnI.
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We are investigating the mechanism by which the Myosin Light Chain Kinase-
Calmodulin (MLCK-CaM) complex phosphorylates Smooth Muscle Myosin
(SMM). MLCK-CaM phosphorylation of SMM is the primary regulator of
smooth muscle contraction, and is required for the catalytic activity of the
myosin motor. We have previously shown that MLCK-CaM-SMM forms
a tightly-associated complex and that MLCK-CaM co-purifies with SMM.
This co-purified MLCK-CaM can phosphorylate SMM which was shown by
actin filament motility in an in vitro motility assay. In addition, using total in-
ternal reflectance fluorescence (TIRF) microscopy, we were able to character-
ize dynamic interactions of MLCKwith monomeric SMM using QuantumDots
(QD) to label MLCK.
The goal of our current study is to determine how a small amount of MLCK is
capable of phosphorylating a much larger amount of SMM. The ratio of MLCK
to SMM in smooth muscle cells is approximately 1:70, yet the MLCK is able to
produce contractions in the cell within seconds. To answer this question, we are
investigating the interaction of MLCK-QD with reconstituted SMM filaments.
This approach is moving more towards the in vivo conditions, and will help us
answer the long term question of how MLCK is phosphorylating SMM within
smooth muscle cells.
We have to reconstituted SMM filaments which are identical in structure to
native SMM filaments, and are capable of being phosphorylated by MLCK.
Our reconstituted filaments are fluorescently labeled and are lightly cross-
linked, which allows them to be stable in the presence of ATP and/or high ionic
strength. We have shown that QD-MLCK co-localizes with our reconstituted
SMM filaments. Our data proposes a mechanism of SMM phosphorylation
by the physical movement of MLCK along a contractile fiber within the smooth
muscle cell.
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Human ventricular cardiac myosin regulatory light chain (MYL2) phosphory-
lation modifies Ser15. This modification affects MYL2 secondary structure and
modulates the Ca2þ sensitivity of contraction in cardiac tissue. Smooth muscle
myosin light chain kinase (smMLCK) is prevalent in uterus and present in other
contracting tissues including cardiac muscle. The recombinant 130 kDa (short)
smMLCK phosphorylated Ser15 in MYL2 in vitro. Specific modification of
Ser15 was verified by direct detection of the phospho group on Ser15 with
mass spectrometry. SmMLCK also specifically phosphorylated myosin regula-
tory light chain Ser15 in porcine ventricular myosin and chicken gizzard
smooth muscle myosin (Ser20 in smooth muscle) but failed to phosphorylate
the myosin regulatory light chain in rabbit skeletal myosin. Michaelis-
Menten Vm and KM constants for Ser15 phosphorylation in MYL2, porcine
ventricular myosin, and chicken gizzard myosin are similar. These data demon-
strate that smMLCK is a specific and efficient kinase for the in vitro phosphor-
ylation of MYL2, cardiac, and smooth muscle myosin. Whether smMLCK
plays a role in cardiac muscle regulation or response to a disease causing stim-
ulus is unclear but it should be considered a potentially significant kinase in car-
diac tissue on the basis of its specificity, kinetics, and tissue expression.
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